Life Sciences Obesity Therapeutics sector
Strategic acquirers, private equity (buyout funds and growth funds) firms, and valuation benchmarks for Life Sciences Obesity Therapeutics
1.1 - About Life Sciences Obesity Therapeutics sector
Companies in the Life Sciences Obesity Therapeutics category research, develop, and commercialize medical interventions that address excess weight and related metabolic disorders. They bring prescription drugs, minimally invasive devices, and evidence-based digital care tools to market, supported by clinical and regulatory expertise. By combining biology-driven discovery with scalable manufacturing and market access capabilities, these providers enable healthcare organizations to deliver effective, safe, and durable weight-loss treatment options.
Typical offerings span next‑generation anti‑obesity pharmaceuticals such as GLP‑1 and dual GIP/GLP‑1 agonists, oral peptide formulations, and long‑acting injectors for sustained dosing. Many also build endoscopic bariatric devices including gastric balloons and sleeves, alongside digital therapeutics with remote monitoring and coaching to improve adherence. Capabilities extend to companion diagnostics and biomarker assays, preclinical and clinical development services, pharmacokinetics and CMC scale‑up, plus market access, payer evidence generation, and post‑marketing safety surveillance.
Primary customers include healthcare providers and obesity clinics, payers and PBMs, and biopharma partners co-developing metabolic treatments. Outcomes delivered typically involve greater weight‑loss efficacy and durability, reduced cardiometabolic risk profiles, accelerated trial execution and regulatory approvals, and improved formulary access with cost-effective adherence support. These companies help purchasers manage utilization, capture real‑world evidence, and scale treatment programs while maintaining safety, compliance, and measurable patient-reported outcomes.
2. Buyers in the Life Sciences Obesity Therapeutics sector
2.1 Top strategic acquirers of Life Sciences Obesity Therapeutics companies
Allurion
- Description: Provider of comprehensive weight-loss solutions that integrate the swallowable, procedure-less Allurion Gastric Balloon with the Allurion Virtual Care Suite, AI-driven mobile app, connected scale and health tracker devices to enable remote monitoring, behavioral coaching and sustained obesity management for patients and healthcare providers.
- Key Products:
- Allurion Gastric Balloon: Swallowable, procedure-less intragastric balloon that occupies stomach space for approximately 4 months to promote weight loss without surgery or endoscopy, then naturally passes
- Allurion Virtual Care Suite: AI-based remote patient monitoring platform with provider dashboard, real-time data, and customizable tiers (basic
- VCS+
- VCS Custom) to manage and support diverse weight-loss therapies
- My Daily Action Bundle (within Allurion Mobile App): Library of evidence-based mindset, movement, nutrition and wellbeing actions in 15 languages, tracked daily in app to build lasting healthy habits
- Allurion Connected Scale & Health Tracker: Bluetooth-enabled devices that integrate with the app to capture weight and activity metrics, giving patients and clinicians continuous insight into progress.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
2.2 - Strategic buyer groups for Life Sciences Obesity Therapeutics sector
M&A buyer group 1: Metabolic Diseases
Liminal Biosciences
- Type: N/A
- Employees: ●●●●●
- Description: Provider of biopharmaceutical research developing novel small-molecule therapeutics targeting metabolic, fibrotic and inflammatory diseases; its pipeline includes GPR84 antagonist LMNL6511 for NASH, IBD and IPF, selective OXER1 antagonists for eosinophilic-driven asthma and dermatitis, and liver-safe GPR40 agonists for type 2 diabetes.
- Key Products:
- LMNL6511 GPR84 antagonist: orally administered small molecule progressing to Phase 1 trials, modulates GPR84 to treat NASH
- IBD and IPF by reducing fibrosis and inflammation
- Selective OXER1 antagonist: targets OXE receptor 1 to block eosinophilic inflammation, intended for asthma and atopic dermatitis, offering novel therapy for allergic diseases
- Liver-safe GPR40 agonist: designed to enhance glucose-dependent insulin secretion for Type 2 diabetes while minimizing liver toxicity, aiming for safer glycaemic control
Buyer group 2: ████████ ████████
●● companiesBuyer group 3: ████████ ████████
●● companies3. Investors and private equity firms in Life Sciences Obesity Therapeutics sector
3.1 - Buyout funds in the Life Sciences Obesity Therapeutics sector
2.2 - Strategic buyer groups for Life Sciences Obesity Therapeutics sector
4 - Top valuation comps for Life Sciences Obesity Therapeutics companies
4.2 - Public trading comparable groups for Life Sciences Obesity Therapeutics sector
Valuation benchmark group 1: Biopharma Protein Therapeutics Companies
Eli Lilly
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of innovative medicines and biotechnology solutions aimed at improving global health. Utilizes advanced scientific research and development to create treatments for various medical conditions, enhancing quality of life and addressing unmet clinical needs in diverse healthcare areas.
- Key Products:
- Insulin Access Programs: Solutions to provide accessible insulin treatments for diabetes management.
- Cancer Treatments: Medicines targeted at oncology to improve patient outcomes.
- Cardiovascular Treatments: Innovative treatments for heart-related conditions.
- Immunology: Solutions addressing autoimmune diseases and enhancing immune system health.
- Neuroscience: Medications to treat neurological disorders including Alzheimer's and schizophrenia.